University of California Berkeley
seal E. O. Lawrence Berkeley National
Laboratory seal
The
Carcinogenic Potency Project

Ethyl acrylate (CAS 140-88-5)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
sto sto sto sto 119m 324m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   sto = stomach. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Ethyl acrylate: All Experiments and Citations in CPDB
The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.
Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.
See Guide to reading the plot for details on each field, using an example of one experiment.
See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

ETHYL ACRYLATE 140-88-5 2653 M f b6c gav 24m24 TR259 : 0 70.4mg 142.mg for MXA 430.mg * P<.03 c 193.mg n.s.s. 1/50 5/50 7/50 for:sqc,sqp. TBA MXB no dre P=1. 134.mg n.s.s. 32/50 31/50 28/50 liv MXB 26.3gm * P<1. 392.mg n.s.s. 3/50 3/50 3/50 liv:hpa,hpc,nnd. lun MXB 2.81gm * P<.6 420.mg n.s.s. 2/50 2/50 3/50 lun:a/a,a/c. 2654 M f b6c inh 24m24 1754i 0 6.44mg Miller;dact,8,1-42;1985 nac tum r no dre P=1. - 119.mg n.s.s. 0/80 0/90 2655 M f b6c inh 6m27 1754j 0 64.4mg lun mix e 4.19gm P<.8 - 403.mg n.s.s. 6/125 4/66 liv mix e no dre P=1. - 312.mg n.s.s. 27/125 12/66 tba ben e no dre P=1. - 155.mg n.s.s. 73/125 35/66 tba mal e no dre P=1. - 199.mg n.s.s. 90/125 38/66 tba mix e no dre P=1. - 93.0mg n.s.s. 109/125 53/66 2656 M f b6c inh 27m27 1754k 0 32.2mg 96.5mg lun mix e 1.26gm * P<.2 - 405.mg n.s.s. 6/125 7/78 8/76 liv vsc e no dre P=1. - 2.20gm n.s.s. 4/125 1/78 0/76 liv mix e no dre P=1. - 614.mg n.s.s. 27/125 9/78 13/76 tba mix e 11.7gm * P<1. - 89.5mg n.s.s. 109/125 61/78 66/76 tba mal e no dre P=1. - 182.mg n.s.s. 90/125 43/78 52/76 tba ben e no dre P=1. - 308.mg n.s.s. 73/125 38/78 38/76 2657 M m b6c gav 24m24 TR259 : 0 70.4mg 142.mg for MXA 260.mg * P<.0005 c 147.mg 523.mg 0/50 5/50 12/50 for:sqc,sqp. for sqp 339.mg * P<.002 c 178.mg 1.04gm 0/50 4/50 9/50 for sqc 687.mg * P<.01 c 296.mg 48.3gm 0/50 2/50 5/50 TBA MXB no dre P=1. 134.mg n.s.s. 30/50 32/50 29/50 liv MXB no dre P=1. 189.mg n.s.s. 17/50 12/50 (6/50) liv:hpa,hpc,nnd. lun MXB no dre P=1. 428.mg n.s.s. 8/50 6/50 5/50 lun:a/a,a/c. 2658 M m b6c inh 24m24 1754i 0 5.36mg Miller;dact,8,1-42;1985 nac tum r no dre P=1. - 99.5mg n.s.s. 0/80 0/90 2659 M m b6c inh 6m27 1754j 0 53.6mg thy ade e 515.mg P<.01 - 199.mg 53.5gm 2/121 7/69 lun mix e no dre P=1. - 302.mg n.s.s. 28/121 12/69 liv mix e no dre P=1. - 254.mg n.s.s. 44/121 19/69 tba ben e no dre P=1. - 208.mg n.s.s. 60/121 27/69 tba mal e no dre P=1. - 160.mg n.s.s. 62/121 31/69 tba mix e no dre P=1. - 132.mg n.s.s. 90/121 44/69 2660 M m b6c inh 27m27 1754k 0 26.8mg 80.4mg lun mix e no dre P=1. - 215.mg n.s.s. 28/121 10/75 (9/76) liv mix e no dre P=1. - 351.mg n.s.s. 44/121 22/75 23/76 liv vsc e no dre P=1. - 1.17gm n.s.s. 5/121 3/75 1/76 tba mix e 2.17gm * P<.9 - 100.mg n.s.s. 90/121 53/75 57/76 tba mal e 300.mg * P<.2 - 104.mg n.s.s. 62/121 34/75 47/76 tba ben e no dre P=1. - 466.mg n.s.s. 60/121 30/75 25/76 2661 R f f34 gav 24m24 TR259 : 0 70.1mg 141.mg for MXA 362.mg * P<.004 c 188.mg 2.29gm 1/50 6/50 11/50 for:sqc,sqp. for sqp 420.mg * P<.01 c 205.mg 37.9gm 1/50 6/50 9/50 TBA MXB 534.mg * P<.7 81.4mg n.s.s. 38/50 44/50 44/50 liv MXB 4.66gm * P<.3 760.mg n.s.s. 0/50 0/50 1/50 liv:hpa,hpc,nnd. 2662 R f f34 inh 24m24 1754m 0 1.53mg Miller;dact,8,1-42;1985 nac tum r no dre P=1. - 28.4mg n.s.s. 0/80 0/90 2663 R f f34 inh 6m27 1754n 0 15.3mg liv bht e no dre P=1. - 199.mg n.s.s. 4/121 1/70 liv sar e no dre P=1. - 280.mg n.s.s. 1/121 0/70 tyf mix e no dre P=1. - 280.mg n.s.s. 0/121 0/70 tba mix e no dre P=1. - 11.5mg n.s.s. 114/121 64/70 tba ben e no dre P=1. - 20.3mg n.s.s. 97/121 54/70 tba mal e no dre P=1. - 59.0mg n.s.s. 72/121 32/70 2664 R f f34 inh 27m27 1754o 0 7.66mg 23.0mg tyf mix e 1.03gm * P<.2 - 253.mg n.s.s. 0/121 1/77 1/78 liv sar e no dre P=1. - 116.mg n.s.s. 1/121 0/77 0/78 liv bht e no dre P=1. - 299.mg n.s.s. 4/121 1/77 2/78 tba ben e no dre P=1. - 48.7mg n.s.s. 97/121 51/77 56/78 tba mal e no dre P=1. - 81.1mg n.s.s. 72/121 41/77 38/78 tba mix e no dre P=1. - 13.7mg n.s.s. 114/121 71/77 73/78 2665 R m f34 gav 24m24 TR259 : 0 70.1mg 141.mg for MXA 71.9mg * P<.0005 c 50.0mg 111.mg 1/50 18/50 36/50 for:sqc,sqp. for sqp 92.9mg * P<.0005 c 62.2mg 152.mg 1/50 15/50 29/50 for sqc 234.mg * P<.0005 c 130.mg 488.mg 0/50 5/50 12/50 mul mle 330.mg \ P<.03 120.mg n.s.s. 1/50 6/50 (1/50) S pan MXA 402.mg \ P<.02 138.mg n.s.s. 0/50 4/50 (0/50) pan:acc,ana. S TBA MXB 94.8mg * P<.01 45.7mg 9.25gm 38/50 40/50 45/50 liv MXB 3.29gm * P<.2 535.mg n.s.s. 0/50 0/50 1/50 liv:hpa,hpc,nnd. 2666 R m f34 inh 24m24 1754m 0 1.07mg Miller;dact,8,1-42;1985 nac tum r no dre P=1. - 19.9mg n.s.s. 0/80 0/90 2667 R m f34 inh 6m27 1754n 0 10.7mg tyf mix e 267.mg P<.2 - 68.6mg n.s.s. 1/120 3/71 liv hpc e no dre P=1. - 199.mg n.s.s. 2/120 0/71 liv bht e no dre P=1. - 199.mg n.s.s. 7/120 0/71 tba ben e 12.8mg P<.4 - 2.72mg n.s.s. 113/120 69/71 tba mal e no dre P=1. - 28.0mg n.s.s. 60/120 33/71 tba mix e noTD50 P<.4 - n.s.s. n.s.s. 116/120 71/71 2668 R m f34 inh 27m27 1754o 0 5.36mg 16.1mg tyf mix e 77.9mg \ P<.03 - 27.0mg n.s.s. 1/120 5/76 (2/75) liv bht e 599.mg * P<.6 - 94.8mg n.s.s. 7/120 5/76 6/75 liv hpc e 1.67gm * P<.6 - 194.mg n.s.s. 2/120 0/76 2/75 tba mix e 5.76mg * P<.08 - 1.43mg n.s.s. 116/120 74/76 75/75 tba ben e 6.27mg * P<.03 - 2.09mg n.s.s. 113/120 72/76 75/75 tba mal e 39.0mg * P<.04 - 16.5mg n.s.s. 60/120 40/76 49/75 2669 R m f34 gav 26w91 2197m 0 40.8mg Ghanayem;txpy,22,497-509;1994 for mix C no dre P=1. - 116.mg n.s.s. 0/16 0/18 liv tum C no dre P=1. - 116.mg n.s.s. 0/16 0/18 2670 R m f34 gav 52w52 2197n 0 143.mg for mix Ck no dre P=1. 36.8mg n.s.s. 0/5 0/5 liv tum Ck no dre P=1. 36.8mg n.s.s. 0/5 0/5 2671 R m f34 gav 52w60 2197o 0 122.mg for sqp Ck 54.7mg P<.08 13.0mg n.s.s. 0/5 2/5 for sqc Ck no dre P=1. 42.0mg n.s.s. 0/5 0/5 liv tum Ck no dre P=1. 42.0mg n.s.s. 0/5 0/5 2672 R m f34 gav 52w91 2197r 0 81.6mg for mix C 116.mg P<.008 + 39.8mg 2.40gm 0/16 4/13 for sqc C 163.mg P<.03 49.1mg n.s.s. 0/16 3/13 for sqp C 535.mg P<.2 87.0mg n.s.s. 0/16 1/13 liv tum C no dre P=1. 167.mg n.s.s. 0/16 0/13

Mutagenicity in Salmonella: negative
SMILES Code for Ethyl acrylate: O=C(OCC)C=C
InChI Code for Ethyl acrylate: InChI=1/C5H8O2/c1-3-5(6)7-4-2/h3H,1,4H2,2H3
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for Ethyl acrylate: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.


Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (tehip@teh.nlm.nih.gov).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10